Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment

Proteome Science

Volumn 9, Issue , 2011, Pages

  Qasim, Muhammad ^a,b   Rahman, Hazir ^a,b   Oellerich, Michael ^a   Asif, Abdul R ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b KOHAT UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

Author keywords

Differential proteomics; Drug toxicology; Hek 293 cells; Mycophenolic acid; Proteome

Indexed keywords

BINDING PROTEIN; CASPASE 3; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q BINDING PROTEIN; ELECTRON TRANSFERRING FLAVOPROTEIN; ELECTRON TRANSFERRING FLAVOPROTEIN BETA; HISTONE H2B; HISTONE H2B TYPE 1 A; HISTONE H2B TYPE 1 C; HISTONE H2B TYPE 1 E; HISTONE H2B TYPE 1 F; HISTONE H2B TYPE 1 G; HISTONE H2B TYPE 1 I; MYCOPHENOLIC ACID; MYOSIN LIGHT CHAIN 2; PEROXIREDOXIN 1; PROFILIN; PROFILIN I; PROTEIN HYDROLYSATE; PROTEIN SET; PROTEOME; RIBOSOME PROTEIN; RIBOSOME PROTEIN S12; STATHMIN; THIOREDOXIN; THIOREDOXIN DOMAIN CONTAINING PROTEIN 12; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LYSATE; CELL PROLIFERATION; CELL STRAIN HEK293; CHROMATIN STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DOWN REGULATION; EMBRYO; ENERGY CONVERSION; ENERGY YIELD; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

RATTUS;

EID: 80053174421     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-57     Document Type: Article

References (64)

1. van Hest RM, van GT, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005, 44:1083-1096. 10.2165/00003088-200544100-00006, 16176120.
2. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118. 10.1016/S0162-3109(00)00188-0, 10878285.
3. Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, Morrone S, et al. Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer 2004, 108:812-817. 10.1002/ijc.11642, 14712481.
4. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G. Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 1991, 51:3886-3890.
5. Park YJ, Ahn HJ, Chang HK, Kim JY, Huh KH, Kim MS, et al. The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line. Cell Signal 2009, 21:356-364. 10.1016/j.cellsig.2008.11.009, 19041939.
6. von VS, Ouyang H, Ley K. Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int 2010, 79-88.
7. Ha H, Kim MS, Park J, Huh JY, Huh KH, Ahn HJ, et al. Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition. Life Sci 2006, 79:1561-1567. 10.1016/j.lfs.2006.05.001, 16740277.
8. Heller T, Asif AR, Petrova DT, Doncheva Y, Wieland E, Oellerich M, et al. Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2. Ther Drug Monit 2009, 31:211-217. 10.1097/FTD.0b013e318196fb73, 19214148.
9. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc) 2009, 45:521-532.
10. Van den Branden C, Ceyssens B, Pauwels M, Van WG, Heirman I, Jie N, et al. Effect of mycophenolate mofetil on glomerulosclerosis and renal oxidative stress in rats. Nephron Exp Nephrol 2003, 95:e93-e99. 10.1159/000074325, 14646361.
11. Stassen PM, Kallenberg CG, Stegeman CA. Use of mycophenolic acid in non-transplant renal diseases. Nephrol Dial Transplant 2007, 22:1013-1019. 10.1093/ndt/gfl844, 17307748.
12. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005, 1:505-526. 10.1517/17425255.1.3.505, 16863458.
13. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003, 25:1-16. 10.1097/00007691-200302000-00001, 12548138.
14. Hubner GI, Eismann R, Sziegoleit W. Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung 2000, 50:936-940.
15. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, Koonin EV, et al. The COG database: an updated version includes eukaryotes. BMC Bioinformatics 2003, 4:41. 10.1186/1471-2105-4-41, 222959, 12969510.
16. Prat O, Berenguer F, Malard V, Tavan E, Sage N, Steinmetz G, et al. Transcriptomic and proteomic responses of human renal HEK293 cells to uranium toxicity. Proteomics 2005, 5:297-306. 10.1002/pmic.200400896, 15672453.
17. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2006, 2:329-337. 10.1038/nchembio790, 16680159.
18. Sohn SH, Ko E, Jo Y, Kim SH, Kim Y, Shin M, et al. The genome-wide expression profile of Paeonia suffruticosa-treated cisplatin-stimulated HEK 293 cells. Environ Toxicol Pharmacol 2009, 28:453-458. 10.1016/j.etap.2009.08.001, 21784042.
19. Suizu F, Ueda K, Iwasaki T, Murata-Hori M, Hosoya H. Activation of Action-Activated MgATPase Activity of Myosin II by Phyosphorylation with MAPK-Activated Protein Kinase-1b (RSK-2). Journal of Biochemistry 2000, 128:435-440.
20. Mondin M, Moreau V, Genot E, Combe C, Ripoche J, Dubus I. Alterations in cytoskeletal protein expression by mycophenolic acid in human mesangial cells requires Rac inactivation. Biochem Pharmacol 2007, 73:1491-1498. 10.1016/j.bcp.2006.12.025, 17258688.
21. Dubus I, L'Azou B, Gordien M, Delmas Y, Labouyrie JP, Bonnet J, et al. Cytoskeletal reorganization by mycophenolic acid alters mesangial cell migration and contractility. Hypertension 2003, 42:956-961. 10.1161/01.HYP.0000097806.45034.45, 14557286.
22. Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Schneeberger EE, et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 2006, 119:2095-2106. 10.1242/jcs.02915, 16638813.
23. Yuan SY, Wu MH, Ustinova EE, Guo M, Tinsley JH, De LP, et al. Myosin light chain phosphorylation in neutrophil-stimulated coronary microvascular leakage. Circ Res 2002, 90:1214-1221. 10.1161/01.RES.0000020402.73609.F1, 12065325.
24. Zhao Y, Rhoades RA, Packer CS. Hypoxia-induced pulmonary arterial contraction appears to be dependent on myosin light chain phosphorylation. Am J Physiol 1996, 271:L768-L774.
25. Ishii T, Yanagawa T. Stress-induced peroxiredoxins. Subcell Biochem 2007, 44:375-384. 10.1007/978-1-4020-6051-9_18, 18084904.
26. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003, 424:561-565. 10.1038/nature01819, 12891360.
27. Mowbray AL, Kang DH, Rhee SG, Kang SW, Jo H. Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J Biol Chem 2008, 283:1622-1627.
28. Schreibelt G, van HJ, Haseloff RF, Reijerkerk A, van der Pol SM, Nieuwenhuizen O, et al. Protective effects of peroxiredoxin-1 at the injured blood-brain barrier. Free Radic Biol Med 2008, 45:256-264. 10.1016/j.freeradbiomed.2008.03.024, 18452719.
29. Jung JY, Kang GC, Jeong YJ, Kim SH, Kwak YG, Kim WJ. Proteomic analysis in cyclosporin A-induced overgrowth of human gingival fibroblasts. Biol Pharm Bull 2009, 32:1480-1485. 10.1248/bpb.32.1480, 19652395.
30. de CM, Silva S, Cruz D, Basso F, Corradi V, Lentini P, et al. Oxidative stress and 'monocyte reprogramming' after kidney transplant: a longitudinal study. Blood Purif 2008, 26:105-110. 10.1159/000110575, 18182807.
31. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005, 80:S221-S234. 10.1097/01.tp.0000186386.13597.cb, 16251855.
32. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009, 28:1505-1517. 10.1038/emboj.2009.101, 2688529, 19369943.
33. Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000, 156:27-35. 10.1016/S0304-3835(00)00434-1, 10840156.
34. Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, et al. Histone deacetylase Inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 2011, 11:7945-7952.
35. Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008, 7:1656-1668. 10.1158/1535-7163.MCT-08-0193, 18566237.
36. Rawe VY, Payne C, Schatten G. Profilin and actin-related proteins regulate microfilament dynamics during early mammalian embryogenesis. Hum Reprod 2006, 21:1143-1153. 10.1093/humrep/dei480, 16428331.
37. Das T, Bae YH, Wells A, Roy P. Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells. J Cell Physiol 2009, 218:436-443. 10.1002/jcp.21618, 2874249, 18937284.
38. Zou L, Ding Z, Roy P. Profilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation. J Cell Physiol 2010, 223:623-629. 2872929, 20143334.
39. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004, 93:242-250. 10.1002/jcb.20187, 15368352.
40. Feichtiger H, Wieland E, Armstrong VW, Shipkova M. The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro. Clin Biochem 2010, 43:208-213. 10.1016/j.clinbiochem.2009.08.023, 19744471.
41. Miyashita H, Kanemura M, Yamazaki T, Abe M, Sato Y. Vascular endothelial zinc finger 1 is involved in the regulation of angiogenesis: possible contribution of stathmin/OP18 as a downstream target gene. Arterioscler Thromb Vasc Biol 2004, 24:878-884. 10.1161/01.ATV.0000126373.52450.32, 15031128.
42. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007, 26:1003-1012. 10.1038/sj.onc.1209864, 16909102.
43. Liu F, Rong YP, Zeng LC, Zhang X, Han ZG. Isolation and characterization of a novel human thioredoxin-like gene hTLP19 encoding a secretory protein. Gene 2003, 315:71-78.
44. Trotta R, Ciarlariello D, Dal CJ, Allard J, Neviani P, Santhanam R, et al. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med 2007, 204:2397-2405. 10.1084/jem.20070419, 2118465, 17875674.
45. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001, 104:119-130. 10.1016/S0092-8674(01)00196-9, 11163245.
46. Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal 2001, 13:7-16. 10.1016/S0898-6568(00)00123-6, 11257442.
47. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368. 10.1016/j.ccr.2005.10.015, 16286244.
48. Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008, 283:12387-12392. 10.1074/jbc.M801387200, 2430998, 18305114.
49. Wu D, Ingram A, Lahti JH, Mazza B, Grenet J, Kapoor A, et al. Apoptotic release of histones from nucleosomes. J Biol Chem 2002, 277:12001-12008. 10.1074/jbc.M109219200, 11812781.
50. Spencer VA, Davie JR. Role of covalent modifications of histones in regulating gene expression. Gene 1999, 240:1-12. 10.1016/S0378-1119(99)00405-9, 10564807.
51. Petrova DT, Heller T, Hitt R, Wieland E, Oellerich M, Armstrong VW, et al. Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition. Ther Drug Monit 2009, 31:31-41. 10.1097/FTD.0b013e318192693e, 19065122.
52. Huang M, Ji Y, Itahana K, Zhang Y, Mitchell B. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res 2008, 32:131-141. 10.1016/j.leukres.2007.03.025, 17462731.
53. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 2006, 103:14519-14524. 10.1073/pnas.0606708103, 1599992, 16971483.
54. Sanchez-Alcazar JA, Khodjakov A, Schneider E. Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res 2001, 61:1038-1044.
55. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000, 192:359-366. 10.1084/jem.192.3.359, 2193213, 10934224.
56. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998, 19:56-59. 10.1038/ng0598-56, 9590289.
57. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
58. Asif AR, Armstrong VW, Voland A, Wieland E, Oellerich M, Shipkova M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie 2007, 89:393-402. 10.1016/j.biochi.2006.09.016, 17069946.
59. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21:1037-1053. 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V, 10786879.
60. blum H, Beier H, Gross HJ. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987, 8:93-99.
61. Luhn S, Berth M, Hecker M, Bernhardt J. Using standard positions and image fusion to create proteome maps from collections of two-dimensional gel electrophoresis images. Proteomics 2003, 3:1117-1127. 10.1002/pmic.200300433, 12872213.
62. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858. 10.1021/ac950914h, 8779443.
63. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
64. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108. 10.1038/nprot.2008.73, 18546601.